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 Abstract 
 Aim: Aplasia cutis congenita (ACC) has been observed after 
fetal exposure to the antithyroid drug methimazole (MMI), 
but not reported after propylthiouracil (PTU), the current anti-
thyroid drug of choice during pregnancy. This occurrence has 
implications for patient information and causal research. 
 Case report: We describe a surviving term co-twin to a 
mother with hyperthyroidism exposed to PTU from concep-
tion to 34 weeks of gestation presenting with ACC at birth. 
 Discussion: The association between PTU exposure and 
ACC is clinically relevant and allows speculation on the eti-
ology. A similar mechanism to the classical MMI-induced 
ACC is postulated, unless a vascular etiology suggested by 
a vanishing twin or maternal hyperthyroidism itself is causal. 
Coincidence of PTU exposure and ACC seems unlikely. 
 Conclusion: ACC in a newborn after PTU exposure during 
pregnancy hitherto observed only after MMI strongly encour-
ages further reports of similar cases that may remain clini-
cally underdiagnosed or unreported. Such confi rmation could 
have signifi cant implications for maternal treatment of hyper-
thyroidism, common in women of childbearing age. 
 Keywords:  antithyroid drugs;  aplasia cutis congenital;  methi-
mazole;  propylthiouracil;  vanishing twin. 
 Introduction 
 Aplasia cutis congenita (ACC) is part of a heterogeneous 
group of disorders characterized by the absence of epider-
mis in a localized or widespread area of skin at birth, sharply 
demarcated and non-infl ammatory in appearance  (1) . This 
anomaly occurs spontaneously in 1 in 2000 births  (2) . Solitary 
defects on the scalp are most common (70 % ) but multiple 
lesions may occur on the face, trunk or limbs, sometimes 
symmetrically. The defects may vary in size (between 0.5 and 
10  cm 2 ) and shape (circular, oval, linear, star-shaped confi gu-
ration). Defects that form early in pregnancy may heal com-
pletely up to delivery and appear as atrophic, membranous 
or parchment-like scars with associated alopecia when on the 
scalp. Less mature defects appear as superfi cial erosions or 
deep ulcerations. The depth may involve the epidermis and 
upper or deep dermis, the subcutaneous tissue and rarely 
the periostium, the skull, the dura or the meninges. ACC is 
mostly a benign isolated defect but can be associated with 
other anomalies or malformation syndromes. A classifi cation 
into nine groups has been proposed by Frieden  (1) . 
 Small and large defects on areas other than the scalp will 
heal spontaneously over several weeks with conservative skin 
care using antiseptic ointment by gradual epithelialization and 
formation of a hairless, atrophic scar. Even small underlying 
bone defects usually close spontaneously during the fi rst year 
of life. By contrast, large or multiple scalp defects usually 
need excision and primary closure, if feasible. Full-thickness 
defects of the scalp, skull and dura are associated with more 
signifi cant morbidity and mortality (20 % ) and may require 
surgical intervention  (3) . 
 There is currently no unifying theory explaining the genesis 
of ACC. Mechanisms causing ACC comprise genetic factors, 
teratogens, vasculature accidents, and trauma or early rupture 
of the amniotic membranes and amniotic bands. 
 Case report 
 We report on a term newborn whose mother (gravida = 2, 
parity = 2) had clinical signs of hyperthyroidism at a pre-
conception check, with goiter, tachycardia and moderate 
exophthalmia. Thyroid function tests (TSH 0.01  mU/L, fT3 
22  pmol/L and fT4 54  pmol/L) and elevated anti-TSH recep-
tor antibodies measured later in pregnancy (10.8  IU/L) con-
fi rmed the diagnosis of Grave ’ s disease. Propylthiouracil 
(PTU) treatment was initiated 2  months before conception 
at 50  mg PTU/day combined with a beta-blocker (propra-
nolol). During pregnancy, fT3 and fT4 normalized, whereas 
TSH remained suppressed and anti-TSH receptor antibodies 
elevated. Antithyroid treatment was stopped at 34  weeks of 
gestation, as the mother was euthyroid. 
 This monochorionic bi-amniotic pregnancy remained 
clinically uneventful until routine ultrasound at 14  weeks 
revealed a vanishing twin syndrome. However, in the absence 
of visible congenital anomaly of the deceased twin or 
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placental infarction at birth, no causal diagnosis was possible. 
Ultrasound follow-up of the surviving twin did not reveal 
fetal goiter and carefully monitored fetal heart rate remained 
in the normal range. No further complications occurred dur-
ing pregnancy; in particular, no signs of fetal hypothyroidism 
were observed. Serology for toxoplasmosis, rubella, CMV, 
listeria, hepatitis B and C and HIV was negative and immu-
nity for varicella was present. 
 The newborn girl (3150  g, 51  cm long, head circumference 
33  cm) had excellent adaptation at birth (APGAR 9/10/10). 
She had no clinical signs of neonatal hyperthyroidism such 
as tachycardia, hyperthermia or goiter, but anti-TSH recep-
tor antibodies were elevated (10  UI/L; normal range  < 1  IU/L) 
and TSH was suppressed (0.07  mU/L). As thyroid function 
tests worsened (TSH  < 0.01  mU/L), antithyroid treatment with 
PTU was initiated on day 12 of life (3 × 5  mg/day initially, 
3 × 2.5  mg/day after improvement of thyroid function tests), 
and was stopped at 30  days of life. Thereafter, thyroid func-
tion tests remained within the normal range. 
 Skin lesions typical for ACC were evident at birth, and the 
association with vanishing twin syndrome allowed classifi ca-
tion into group 5 (Table  1 ). Lesions were symmetrical. The 
largest lesion on the right fl ank was round in shape and super-
fi cially eroded (1  cm × 0.5  cm) and surrounded by a scar of 
7  cm × 2.5  cm vanishing into star-shaped, parchment-like skin 
on the left fl ank that was 3  cm long (Figure  1 ). Four additional 
discrete linear scars were noted on each inner infrapatellar 
region and each thigh. No scalp lesions or associated anoma-
lies were present. Conservative treatment with antiseptics led 
to rapid and complete scarring. 
 Discussion 
 Maternal hyperthyroidism may pose a risk to the fetus. To 
minimize the risk of complications such as fetal cardiac fail-
ure, craniostenosis, intrauterine growth restriction, prematu-
rity, fetal hydrops and intrauterine death  (4) , pregnancy should 
be delayed until hyperthyroidism is under control. However, 
antithyroid treatment during pregnancy is recommended for 
newly developing hyperthyroidism, as well as recurrences, in 
the expecting mother  (2) . Lowest possible doses of antithy-
roid drugs are recommended to keep fT4 levels within the 
 Table 1  Classifi cation of ACC according to Frieden  (1) .
Group Description
1 Solitary scalp ACC (86 % ), with an autosomal dominant inheritance pattern or spontaneous
2 Scalp involvement with limb anomalies; Adam Oliver syndrome is a subtype with distal limb reduction anomalies
3 Scalp ACC with epidermal and sebaceous nevi involving the scalp
4 ACC often with a hair collar overlying a deeper embryologic malformation such as meningomyelocele, gastroschisis, 
omphalocele, etc.
5 Extensive truncal and limb ACC in a linear or star-shaped confi guration, associated with fetus papyraceous or placental infarction
6 ACC with simplex, junctional or dystrophic types of epidermolysis bullosa (EB)
7 Localized ACC to the limbs with no EB
8 ACC due to teratogens such as methimazole or carbimazole, misoprostol or valproic acid, or to intrauterine infection with 
herpes simplex virus or varicella-zoster virus
9 ACC linked to malformation syndromes
 Figure 1  Aplasia cutis congenita of the right fl ank on day 5. Note 
the linear confi guration with the adjacent wrinkly skin, a sign of a 
much larger fetal lesion. 
high normal reference range and at the same time prevent pla-
cental drug-crossing causing fetal hypothyroidism, goiter and 
abnormal brain development  (5) . 
 In 1 % – 5 % of cases, Grave ’ s disease during pregnancy will 
lead to fetal and neonatal hyperthyroidism through placental 
crossing of thyroid-stimulating antibodies (thyrotropin-recep-
tor antibodies). The risk of neonatal hyperthyroidism may be 
assessed by maternal thyrotropin-receptor antibodies at the 
beginning of the third trimester  (6) . Fetal signs of hyperthy-
roidism are poor growth and tachycardia, whereas neonates 
may present with tachycardia in addition to hyperactivity, irri-
tability, hyperthermia and weakness. 
 To date, PTU is considered the antithyroid drug of choice 
during pregnancy compared to methimazole (MMI), which 
has considerable adverse fetal effects. Intrauterine exposure 
to MMI has been associated with congenital anomalies, in 
particular aplasia cutis congenita  (2, 7) , as well a syndrome 
called MMI embryopathy characterized by facial anomalies, 
choanal or esophageal atresia, tracheo-esophageal fi stula, 
growth restriction, developmental anomalies and isolated 
imperforate anus  (8) . The incidence of spontaneous or inher-
ited ACC is approximately 1:2000 births  (2) and is limited in 
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the vast majority of cases to the scalp (Table  1 ); the ACC rate 
after maternal MMI treatment, however, remains unknown. 
 PTU and MMI cross the placenta similarly  (9, 10) . However, 
the theoretical risk for PTU is lower owing to higher levels of 
drug binding to serum proteins  (11) . Both drugs are classifi ed 
as category D by the Food and Drug Administration because 
of placental transfer and the potential for fetal hypothyroidism 
 (12) . A similar incidence of major congenital anomalies has 
been reported after PTU (3 % ) and MMI (2.7 % ) exposure in 
utero  (13) . Several studies failed to show an increase in major 
congenital malformations in infants of hyperthyroid mothers 
treated with PTU  (14 – 16) . A study including 65 infants born 
to mothers with Grave ’ s disease treated with either PTU or 
MMI again found no excess congenital anomalies  (17) . No 
case of ACC has been observed after maternal PTU treat-
ment so far, but associations with other congenital anomalies 
have been reported, including congenital hip dislocation  (18) , 
undescended testes and muscular hypotony  (19) , hypospadias 
and aortic atresia  (7) , choanal atresia  (20) , ventricular sep-
tum defect, pulmonary stenosis, patent ductus arteriosus  (13) 
and syndactily after combined PTU and  131 I therapy  (21) . A 
cause of effect remains questionable in these mostly frequent 
anomalies. 
 The ACC reported here may be classifi ed as group 5 (Table 
 1 ) because of its association with a vanishing twin. However, 
in utero exposure to PTU is of concern and teratogenic origin 
(Table  1 ; group 8) may also be postulated. 
 According to the current pathogenic hypothesis, symmetri-
cal ACC is caused by a vascular disruption, either ischemic 
or thrombotic, affecting the dermo-epidermal development. 
Intra-uterine death of a twin may cause release of thrombotic 
material, promoting ACC in the surviving twin in the case of 
vascular shunts. This is usually associated with extensive pla-
cental infarctions, disseminated intravascular coagulation and 
other direct and usually severe injuries to the surviving twin, 
which we failed to fi nd in our index case  (22, 23) . 
 So far, only MMI exposure has been incriminated as a cause 
of ACC (group 8), although MMI and PTU have the same 
pharmacological effect on the thyroid. Both inhibit thyroid 
hormone synthesis by acting on thyroid-peroxidase-mediated 
iodination of tyrosine residues in thyroglobulin, an important 
step in thyroxine and triiodothyronine synthesis  (12) . MMI 
has faster onset of action and prolonged activity, and read-
ily crosses the placenta in the absence of binding proteins, 
and thus theoretically presents a higher risk to the fetus. Our 
fi nding suggests a similar teratogenic effect of PTU, possi-
bly of vascular origin, unless the underlying maternal thyroid 
disease itself caused ACC. 
 Indeed, it has been suggested that hyperthyroidism per se is 
teratogenic  (2, 24) , but it has not been directly associated with 
ACC. Other anamnestic risk factors for ACC, including genetic 
components, other teratogens, vascular accidents, trauma or 
early rupture of the membranes with possible amniotic bands, 
were absent. Furthermore, our case may have resulted from 
the coincidence of spontaneously occurring ACC and PTU 
exposure in utero. Coincidence of ACC (1:2000 births) and 
PTU treatment (1:100 – 1:2000 pregnancies)  (25) has a theo-
retical incidence of 1 in 2 – 4 million births, and would thus 
be an extremely rare event. For Switzerland alone, such a 
coincidence would present only every 30 – 60  years. Thus, it is 
unlikely that this is the cause of our case, which is further sup-
ported by the fact that ACC group 5 is not a common presen-
tation. However, coincidence with a vanishing twin, despite 
remaining rare, is more likely  (26) . 
 In conclusion, the reported new association between 
ACC and fetal exposure to PTU remains suspect for a drug-
induced pathology. To date, ACC has been reported only 
after exposure to MMI. Coincidence seems unlikely. Our 
fi nding allows speculation on a vascular etiology of ACC 
after maternal antithyroid drug exposure. The teratogenic 
risk of PTU is considered low at present, but its safety 
may be challenged by similar reports on ACC after PTU 
exposure in utero. As the clinical appearance of ACC can 
vary greatly and may remain undiagnosed when minimal 
or healed (wrinkly or parchment-like skin), neonatologists 
and dermatologists should complete a case history regard-
ing drug intake during pregnancy and search for lesions 
in babies of mothers on PTU treatment. Until more cases 
have been reported or new strategies for maternal antithy-
roid treatment during pregnancy are developed, PTU will 
most likely remain the drug of choice, but a more systematic 
investigation of similar cases is warranted. If our report is 
confi rmed, it could have signifi cant implications for mater-
nal treatment of hyperthyroidism, a common pathology in 
women of childbearing age. 
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